Jun 2026 (Q2 FY26) — Aug 5, 2026
Sight Sciences Q2 FY26 — Strong Revenue Growth and Raised Guidance
Read the full callSight Sciences (SGHT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Sight Sciences earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 23.4 | +19.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -16.6 | +43.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -4.4 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$8.28 −5.91% · −$0.52
Performance +130.0% 1Y
1Y: $3.6 on 15 Oct 2025 → $8.28. High $9.36 (30 Sept 2026), low $3.45 (16 Oct 2025).
- Previous close
- $8.8
- 52-week range
- $3.45 – $9.36
- One year
- +140.00%
Overview
- Symbol
- SGHT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Sight Sciences earnings calls (SGHT)
Financials
What the filings say
Net profit, year on year: +63% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 20 | 19 | 18 | 20 | 20 | 20 | 20 | 23 |
| Operating profit | -11 | -12 | -14 | -12 | -8 | -4 | -12 | -4 |
| Operating margin | −55.7% | −62.5% | −79.2% | −59.6% | −39.7% | −18.0% | −63.0% | −16.6% |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -11 | -12 | -14 | -12 | -8 | -4 | -13 | -4 |
| Tax rate | −1.5% | −0.3% | −0.3% | −0.3% | 1.0% | −0.2% | −0.1% | −0.6% |
| Net profit | -11 | -12 | -14 | -12 | -8 | -4 | -13 | -4 |
| EPS ($ per share) | -0.22 | — | -0.28 | -0.23 | -0.16 | — | -0.24 | -0.08 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -90 | -153 | -239 | -295 | -346 | -385 |
| Total liabilities | 44 | 48 | 53 | 46 | 55 | 51 |
| Fixed assets | 1 | 1 | 2 | 2 | 2 | 2 |
| Total assets | 73 | 280 | 213 | 167 | 143 | 115 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -32 | -53 | -76 | -47 | -22 | -30 |
| Cash from investing | -1 | -1 | -1 | -1 | -0 | -0 |
| Cash from financing | 73 | 253 | 1 | 1 | 5 | 2 |
| Net cash flow | 40 | 199 | -76 | -47 | -18 | -28 |
| Capital expenditure | -1 | -1 | -1 | -1 | -0 | -0 |
| Free cash flow | -33 | -53 | -77 | -48 | -23 | -30 |
Insider filings
60 filings between Nov 11, 2025 and Oct 2, 2026.
Open market
decisions to buy or sellPurchases
$184.8K
2 purchases by 1 insider
Sales
$2.87M
38 sales by 6 insiders
68% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 14
- Award — granted as compensation
- 6
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Badawi Paul | — | $957.2K | Oct 1, 2026 |
| Bauerlein Alison | — | $665.8K | Oct 2, 2026 |
| HAYDEN JEREMY B. | — | $635.1K | Jul 6, 2026 |
| Badawi David | — | $245.0K | Oct 1, 2026 |
| Rodberg James | — | $203.5K | Oct 2, 2026 |
| Encrantz Staffan | $184.8K | — | Jun 10, 2026 |
| Taylor Brenton | — | $158.8K | Oct 2, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Bauerlein Alison Chief Operating Officer | Sale 10b5-1 plan | 25,260 | $223.6K |
| Oct 2, 2026 | Taylor Brenton EVP, Operations & R&D | Sale 10b5-1 plan | 2,988 | $26.5K |
| Oct 2, 2026 | Rodberg James Chief Financial Officer | Sale 10b5-1 plan | 7,208 | $63.8K |
| Oct 1, 2026 | Badawi David Chief Technology Officer | Sale 10b5-1 plan | 7,797 | $70.6K |
| Oct 1, 2026 | Badawi Paul President and CEO | Sale 10b5-1 plan | 29,653 | $268.3K |
| Aug 10, 2026 | Rashid Kashif Chief Legal Officer | Award | 181,818 | $0 |
| Jul 6, 2026 | HAYDEN JEREMY B. Chief Legal Officer | Sale 10b5-1 plan | 12,733 | $70.1K |
| Jul 6, 2026 | Badawi David Chief Technology Officer | Sale 10b5-1 plan | 7,418 | $40.9K |
| Jul 2, 2026 | Bauerlein Alison Chief Operating Officer | Sale 10b5-1 plan | 24,184 | $129.6K |
| Jul 2, 2026 | Rodberg James Chief Financial Officer | Sale 10b5-1 plan | 6,902 | $37.0K |
| Jul 1, 2026 | Taylor Brenton EVP, Operations & R&D | Sale 10b5-1 plan | 2,829 | $15.3K |
| Jul 1, 2026 | Badawi Paul President and CEO | Sale 10b5-1 plan | 28,684 | $155.5K |
| Jun 10, 2026 | Encrantz Staffan Director | Purchase | 14,100 | $68.8K |
| Jun 4, 2026 | Encrantz Staffan Director | Award | 28,261 | $0 |
| Jun 4, 2026 | Mazzacco Catherine Director | Award | 28,261 | $0 |
| Jun 4, 2026 | Fountain Tamara Director | Award | 28,261 | $0 |
| Jun 4, 2026 | Burbach Gerhard F Director | Award | 28,261 | $0 |
| Jun 4, 2026 | Zurbay Donald Director | Award | 28,261 | $0 |
| May 18, 2026 | Bauerlein Alison Chief Operating Officer | Sale 10b5-1 plan | 12,728 | $65.2K |
| Apr 6, 2026 | Rodberg James Chief Financial Officer | Sale 10b5-1 plan | 7,231 | $25.7K |
| Apr 6, 2026 | HAYDEN JEREMY B. Chief Legal Officer | Sale 10b5-1 plan | 13,761 | $48.9K |
| Apr 2, 2026 | Bauerlein Alison Chief Operating Officer | Sale 10b5-1 plan | 25,874 | $90.0K |
| Apr 2, 2026 | Badawi David Chief Technology Officer | Sale 10b5-1 plan | 8,168 | $28.4K |
| Apr 1, 2026 | Taylor Brenton EVP, Operations & R&D | Sale 10b5-1 plan | 2,869 | $10.6K |
| Apr 1, 2026 | Badawi Paul President and CEO | Sale 10b5-1 plan | 29,244 | $108.2K |
| Feb 19, 2026 | Badawi David Chief Technology Officer | Option exercise | 21,270 | $4.9K |
| Feb 3, 2026 | Taylor Brenton EVP, Operations & R&D | Award | 100,464 | $0 |
| Feb 3, 2026 | Badawi Paul President and CEO | Award | 154,560 | $0 |
| Feb 3, 2026 | Badawi David Chief Technology Officer | Award | 64,915 | $0 |
| Feb 3, 2026 | HAYDEN JEREMY B. Chief Legal Officer | Award | 115,920 | $0 |
| Feb 3, 2026 | Bauerlein Alison Chief Operating Officer | Award | 127,512 | $0 |
| Feb 3, 2026 | Rodberg James Chief Financial Officer | Award | 86,940 | $0 |
| Jan 16, 2026 | Badawi David Chief Technology Officer | Sale 10b5-1 plan | 4,836 | $32.0K |
| Jan 16, 2026 | Rodberg James Chief Financial Officer | Sale 10b5-1 plan | 2,616 | $17.3K |
| Jan 16, 2026 | Badawi Paul President and CEO | Sale 10b5-1 plan | 22,362 | $148.0K |
| Jan 16, 2026 | HAYDEN JEREMY B. Chief Legal Officer | Sale 10b5-1 plan | 6,308 | $41.8K |
| Jan 6, 2026 | Badawi Paul President and CEO | Sale | 11,870 | $88.8K |
| Jan 6, 2026 | HAYDEN JEREMY B. Chief Legal Officer | Sale 10b5-1 plan | 1,785 | $13.4K |
| Jan 6, 2026 | Badawi David Chief Technology Officer | Sale | 3,695 | $27.6K |
| Jan 6, 2026 | Taylor Brenton EVP, Operations & R&D | Sale | 619 | $4.6K |
| Jan 6, 2026 | Rodberg James Chief Financial Officer | Sale | 594 | $4.4K |
| Jan 6, 2026 | Bauerlein Alison Chief Operating Officer | Sale | 9,647 | $72.2K |
| Jan 5, 2026 | Bauerlein Alison Chief Operating Officer | Sale | 10,896 | $85.2K |
| Jan 5, 2026 | HAYDEN JEREMY B. Chief Legal Officer | Sale 10b5-1 plan | 9,385 | $73.4K |
| Jan 5, 2026 | Badawi David Chief Technology Officer | Sale | 3,051 | $23.9K |
| Jan 5, 2026 | Rodberg James Chief Financial Officer | Sale | 4,405 | $34.4K |
| Jan 2, 2026 | Badawi Paul President and CEO | Sale | 25,356 | $188.4K |
| Jan 2, 2026 | Badawi David Chief Technology Officer | Sale | 2,914 | $21.7K |
| Dec 26, 2025 | Badawi David Chief Technology Officer | Option exercise | 21,270 | $4.9K |
| Dec 16, 2025 | Encrantz Staffan Director | Purchase | 13,958 | $116.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Sight Sciences, Inc.
Free account. Everything above stays public.
Write why you follow Sight Sciences, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading